numbers N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, and N01-HC-45133 and grant numbers U01 HL080295 and R01 HL087652 from the NHLBI and R01 AG023629 from the NIA, with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at http://www.chs- nhlbi.org/pi.htm. DNA handling and genotyping was supported in part by National Center for Research Resources grant M01-RR00425 to the Ce- dars-Sinai General Clinical Research Center Genotyping core and National Institute of Diabetes and Digestive and Kidney Diseases grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The FHS phenotype–genotype analyses were supported by the NIA grant num- bers R01AG029451, R01AG028321, R01AG033193, and R01 AG031287. The FHS of the NHLBI of the National Institutes of Health (NIH) and Boston University School of Medicine were supported by the NHLBI’s FHS contract number N01-HC-25195 and its contract with Affymetrix, Inc. for genotyping services (contract number N02-HL-6-4278). Analyses re- flect intellectual input and resource development from the FHS investiga- tors participating in the SNP Health Association Resource project. A portion of this research was conducted using the Linux Cluster for Genetic Analy- sis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Bos- ton Medical Center. D.P.K.’s effort was supported by a grant from the Na- tional Institute of Arthritis, Musculoskeletal and Skin Diseases and the NIA (R01 AR/AG 41398). The RS is supported by the Erasmus Medical Center and Erasmus University Rotterdam; the Netherlands Organisation for Sci- entific Research (NWO); the Netherlands Organisation for Health Research and Development (ZonMw); the Research Institute for Diseases in the El- derly; the Ministry of Education, Culture and Science; the Ministry of Health, Welfare and Sports; and the European Commission (DG XII). The genetic analyses were supported by the Netherlands Organization for Sci- entific Research grant number 175.01.2005.011. This study was supported by the Netherlands Genomics Initiative-Sponsored Netherlands Consor- tium for Healthy Aging (nr 050-060-810). The work of S.W. was supported by Netspar. The AGES-Reykjavik is funded by NIH contract number N01- AG-12100, the NIA Intramural Research Program, Hjartavernd (the Icelan- dic Heart Association), and the Althingi (the Icelandic Parliament). Genotyping was conducted at the NIA Intramural Research Program Labo- ratory of Neurogenetics. The Leiden Longevity Study was supported by the Innovation Oriented research Program on Genomics, the Centre for Medi- cal Systems Biology, and the Netherlands Consortium for Healthy Aging in the framework of the Netherlands Genomics Initiative, the Netherlands Or- ganization for Scientific Research, the Netherlands Organization for Health Research and Development (ZonMw), the Danish National Programme for Research Infrastructure 2007 from the Danish Agency for Science Technol- ogy and Innovation, and Unilever PLC, UK. The Longevity Consortium, funded by the NIA, grant number U19 AG023122, provided administrative resources to CHARGE investigators for this phenotype as well as scientific opportunity funds to conduct follow-up genotyping. The Danish 1905 Co- hort Survey was supported by grants from the Danish National Research Foundation and NIH/NIA grant P01 AG08761. The Danish Aging Research Center is supported by a grant from the Velux Foundation. The Atheroscle- rosis Risk in Communities Study is carried out as a collaborative study supported by NHLBI contract numbers N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01- HC-55022, R01HL087641, R01HL59367, and R01HL086694; National Human Genome Research Institute contract number U01HG004402; and NIH contract number HHSN268200625226C. Infrastructure was partly supported by grant number UL1RR025005, a component of the NIH and

References

Perls T, Shea-Drinkwater M, Bowen-Flynn J, et al. Exceptional familial clustering for extreme longevity in humans. J Am Geriatr Soc.

;

(

):

–

Perls T, Kohler IV, Andersen S, et al. Survival of parents and siblings of supercentenarians. J Gerontol A Biol Sci Med Sci.

;

(

):

–

Perls T, Terry D. Genetics of exceptional longevity. Exp Gerontol.

;

(

):

–

Hjelmborg JV, Iachine I, Skytthe A, et al. Genetic influence on human lifespan and longevity. Hum Genet.

;

(

):

–

Herskind AM, M

ue M, Holm NV, Sorensen TI, Harvald B, Vaupel JW. The heritability of human longevity: a population-based study of

Danish twin pairs born

-

Hum Genet.

;

(

):

–

Iachine IA, Holm NV, Harris JR, et al. How heritable is individual susceptibility to death? The results of an analysis of survival data on Danish, Swedish and Finnish twins. Twin Res.

;

(

):

–

Schoenmaker M, de Craen AJM, de Meijer PHEM, et al. Evidence of genetic enrichment for exceptional survival using a family approach: the Leiden Longevity Study. Eur J Hum Genet.

;

(

):

–

Butler RN, Austad SN, Barzilai N, et al. Longevity genes: from primi- tive organisms to humans. J Gerontol A Biol Sci Med Sci.

;

(

):

–

Browner WS, Kahn AJ, Ziv E, et al. The genetics of human longevity. Am J Med.

;

(

):

–

Franceschi C, Olivieri F, Marchegiani F, et al. Genes involved in im- mune response/inflammation, IGF

/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mech Ageing Dev.

;

(

):

–

van Heemst D, Beekman M, Mooijaart SP, et al. Reduced insulin/ IGF-

signalling and human longevity. Aging Cell.

;

(

):

–

Holzenberger M, Dupont J, Ducos B, et al. IGF-

receptor regulates lifespan and resistance to oxidative stress in mice. Nature.

;

(

):

–